Article Text

Download PDFPDF
Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


What are the effects of ziprasidone compared with other atypical antipsychotics in people with schizophrenia and schizophrenia-like psychoses?


Global state: no clinically important response (as defined by each study eg, <50% reduction on a rating scale, or global impression less than much improved); leaving study early (for any reason such as adverse events, inefficacy of treatment, weight gain etc.).



Systematic review with meta-analysis.

Data sources:

Cochrane Schizophrenia Group's Specialised Register was searched from inception to April 2007 for randomised controlled trials (RCTs). Reference lists of identified studies were hand searched. The first authors of the included studies were contacted for missing information, and drug companies were contacted for additional data.

Study selection and analysis:

Reviewers appraised studies and selected RCTs that compared oral ziprasidone with oral forms of risperidone, quetiapine, olanzapine, amisulpride, aripiprazole, clozapine, sertindole or zotepine in people with schizophrenia and schizophrenia-like psychoses. There were no restrictions on dose and language. Data were extracted independently. Weighted mean differences (MDs) were calculated for continuous data. Dichotomous data were used to …

View Full Text


  • Source of funding Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern, Germany. Bundesministerium für Bildung und Forschung, Germany.


  • Competing interests TSS has been paid for consulting for AstraZeneca, Eli Lilly, Janssen and Pfizer. LFJ has received research grants from Glaxo SmithKline, Novartis and AstraZeneca.

Linked Articles